Besufetamig clinical trials
Also written ONO-4685.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses besufetamig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ONO-4685
- 4
Studies by the year they started
4 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Ono Pharmaceutical Co., Ltd. (2) · Ono Pharmaceutical Co. Ltd (2)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test besufetamig.
- Aug 2027Study of ONO-4685 in Patients With Relapsed or Refractory T Cell LymphomaPhase 1 · Ono Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses besufetamig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of ONO-4685 in Patients With Relapsed or Refractory T Cell LymphomaActive, not recruitingPhase 1Ono Pharmaceutical Co., Ltd.NCT05079282Written as ONO-4685
- A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLLActive, not recruitingPhase 1Ono Pharmaceutical Co., Ltd.NCT06547528Written as ONO-4685
- Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685CompletedPhase 1Ono Pharmaceutical Co. LtdNCT05332704Written as ONO-4685
- Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male SubjectsCompletedPhase 1Ono Pharmaceutical Co. LtdNCT04079062Written as ONO-4685
Codes
What other systems call besufetamig · ClinicalTrials.gg INT015742
- UNII (FDA) 8YCQ8727FBBESUFETAMIGOne source FDA
- NCI Thesaurus C185163BesufetamigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8YCQ8727FB | BESUFETAMIG | One source FDA |
| NCI Thesaurus | C185163 | Besufetamig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.